Ke halaman utama

Halaman 2 - Kemoterapi Dokter Terbaik di Turquia - TOP-57 dokter

Konten memenuhi Kebijakan Editorial Bookimed dan ditinjau secara medis oleh

Fahad Mawlood

Alp Özkan

  • 4.6 Sangat baik 513 ulasan
  • 26 tahun pengalaman
  • Turquia, Istambul, Anadolu Medical Center
  • Profesor Alp Özkan adalah salah satu spesialis limfoma terkemuka di Turki, dengan pengalaman lebih dari 20 tahun yang berfokus pada onkologi pediatrik di Anadolu Medical Center.

    • Kepala Departemen Onkologi Pediatrik sejak 2011
    • Telah menerbitkan lebih dari 70 artikel ilmiah tentang kanker masa kanak-kanak
    • Penulis 5 buku tentang hematologi-onkologi pediatrik
    • Pelatihan di MD Anderson Cancer Hospital di AS
    • Penerima Penghargaan Ilmiah Turki dalam Onkologi Pediatrik
  • Baca selengkapnya
Kemoterapi
$1,650 - $6,500
Info

Tugba Akin Telli

  • 5 Sangat baik 51 ulasan
  • 17 tahun pengalaman
  • Turquia, Istambul, Istanbul Florence Nightingale Hospital
  • Saat Ini
    Rumah Sakit Istanbul Florence Nightingale
    Onkologi Medis

    2022-2024
    Rumah Sakit Memorial Şişli
    Spesialis Onkologi Medis

    2021-2022
    Institut Jules Bordet
    Beasiswa Penelitian Klinis

    2020-2022
    Rumah Sakit Pendidikan dan Penelitian Universitas Marmara Pendik
    Spesialis Onkologi Medis

    2019-2019
    Institut Jules Bordet
    Beasiswa Penelitian Klinis

    2016-2019
    Fakultas Kedokteran Universitas Marmara, Departemen Onkologi Medis
    Fellowship Onkologi Medis

    2014-2016
    Rumah Sakit Umum Golbasi
    Spesialis Penyakit Dalam

    2013-2014
    MD Anderson Cancer Center
    Observership

    2013
    Rumah Sakit Bellvitge, Barcelona, Spanyol
    Observership

    2009 -2014
    Fakultas Kedokteran Universitas Hacettepe
    Residensi Penyakit Dalam

  • Baca selengkapnya
Kunjungan dokter
Harga berdasarkan permintaan
Info

Sebnem Izmir Guner

  • 4.6 Sangat baik 202 ulasan
  • 33 tahun pengalaman
  • Turquia, Istambul, Hisar Hospital Intercontinental
  • Prof. Dr. Şebnem İzmir Güner was born in 1970 in Istanbul and took her first steps in her medical career at Istanbul University Faculty of Medicine. Successfully completing her undergraduate and medical education here between 1987-1993, Güner received her internal medicine specialty training at Istanbul University Cerrahpaşa Faculty of Medicine from 1995 to 2000. Deepening her interest in hematology, Prof. Dr. Güner completed her hematology subspecialty training at Cerrahpaşa Faculty of Medicine again between 2003-2006, solidifying her expertise in this field.
    Prof. Dr. Güner’s professional journey began as an internal medicine specialist at Istanbul Education and Research Hospital from 2000 to 2003. She established the Hematology Clinic at the same hospital from 2006 to 2010 and served as the responsible physician. Here, she developed innovative approaches in the treatment of patients and made significant contributions to the field of hematology. From 2010 to 2016, she established the Hematology Clinic, Therapeutic Apheresis, and Adult Bone Marrow Transplantation Center at Medicalpark Bahçelievler Hospital and served as the responsible physician. During this period, she conducted studies that set national and international standards in the field of hematology.
    Between 2016-2018, Prof. Dr. Güner took on similar roles at Şişli Kolon International Hospital, where she was also the founder and responsible physician of the Hematology Clinic, Therapeutic Apheresis, and Adult Bone Marrow Transplantation Center. Güner, who became an associate professor in 2017, obtained her professorship title in 2023. Between 2019-2024, she worked at Memorial Şişli Hospital in the Hematology Clinic, Therapeutic Apheresis, and Adult Bone Marrow Transplantation Center.
    Prof. Dr. Şebnem İzmir Güner is recognized for her scientific contributions, with over 19 articles published in international peer-reviewed journals. Additionally, she has over 18 articles published in national peer-reviewed journals and 51 presentations at national scientific meetings that have been published in proceedings books. She has also made a name for herself in the academic world with over 18 presentations at meetings and published in proceedings books. Güner, who has held positions on the boards of domestic hematology associations and has active memberships, has crowned her success with more than three awards given at universities and conferences.
    Prof. Dr. Şebnem İzmir Güner, who speaks English and German, is also recognized as an educator. In this capacity, she has contributed to the training of young doctors in the field of hematology, providing education to research assistant doctors and students.
    Prof. Dr. Şebnem İzmir Güner has established a respected place in the field of hematology with her achievements and scientific contributions throughout her professional life, continuing her career as a physician who inspires her patients and colleagues.

    MEDICAL INTERESTS

    • Leukemia
    • Lymphoma
    • Multiple myeloma
    • Bone marrow transplantation
    • Anemia
    • Bleeding and coagulation disorders
    • Hemophilia
  • Baca selengkapnya
Kemoterapi
$1,500 - $2,500
Info

Oguzhan Babacan

  • 4.6 Sangat baik 202 ulasan
  • 28 tahun pengalaman
  • Turquia, Istambul, Hisar Hospital Intercontinental
  • Assoc. Prof. Dr. Oğuzhan BABACAN completed his undergraduate, specialty and sub-specialty education at GATA Military Medical Faculty/Ankara. After becoming a specialist in Pediatrics, he worked in the field of Social Pediatrics for two years, where Healthy Baby Monitoring and vaccine follow-up were carried out. Then, she completed her subspecialty training in Pediatric Hematology and Oncology and continued her studies in the field of pediatric blood and cancer diseases. In addition to the treatment of children suffering from leukemia, lymphoma, solid tumors and other blood diseases, she has been working in the Bone Marrow Transplantation (Transplant) Unit for 13 years in Allogeneic (unrelated and intrafamilial), Autologous (from the patient himself) and Haploidentical (partially HLA compatible) hematopoietic stem cell transplantation. In 2018, he received the title of Associate Professor in the field of Pediatric Hematology and Oncology Science/Art.

     

    MEDICAL AREAS OF INTEREST

    Healthy baby follow-up and vaccinations

    Lymph node enlargement

    Pediatric patients with anemia (anemia)

    Leukemia

    Lymphoma

    Bone Marrow Transplant

    ITP

    Thalassemias

    Hemophiliacs

    Solid tumors

    Hemangioma

    Childhood blood disorders

    Children with frequent infections

    Fever of unknown origin

    Malnutrition in children

  • Baca selengkapnya
Kemoterapi
$1,500 - $2,500
Info

Mustafa Özdoğan

  • 4.6 Sangat baik 124 ulasan
  • 26 tahun pengalaman
  • Turquia, Antália, Memorial Antalya Hospital
    • Lebih dari 20 tahun pengalaman dalam kemoterapi, menggunakan teknik terapi target dan imunoterapi.
    • Pelatihan internasional di Turki, mengkhususkan diri dalam onkologi medis dan metode kemoterapi.
    • Anggota Asosiasi Onkologi Klinis Eropa dan Amerika.
    • Telah menerbitkan lebih dari 40 artikel tentang pengobatan kanker, termasuk kemajuan dalam kemoterapi.
    • Telah menjadi Profesor dalam bidang onkologi medis sejak tahun 2011.
  • Baca selengkapnya
Kunjungan dokter
Harga berdasarkan permintaan
Info

Necdet Uskent

  • 4.6 Sangat baik 513 ulasan
  • 46 tahun pengalaman
  • Turquia, Istambul, Anadolu Medical Center
  • Profesor Onkologi dan Hematologi – Dr. Uskent membawa keahlian akademisnya ke perawatan pasien di Pusat Medis Anadolu.

    • Berspesialisasi dalam kemoterapi dan pengobatan hematologi
    • Latar belakang akademis memastikan protokol pengobatan yang terkini
    • Bekerja di pusat medis terkemuka di Turki
  • Baca selengkapnya
Kemoterapi
$1,650 - $6,500
Info

Tahsin Ozadli

  • 4.9 Sangat baik 53 ulasan
  • 23 tahun pengalaman
  • Turquia, Istambul, Valued Med Hub Hospitals
  • Education and Expertise

    Selcuk University Meram Faculty of Medicine - Medical Education

    Dr.Abdurrahman Yurtaslan Anakara Oncology Training and Research Hospital Medical Oncology Specialization

     

    Experience

    Malatya State Hospital Internal Diseases Clinic

    Ankara Oncology Hospital Medical Oncology Clinic

    Erzurum Regional Training and Research Hospital Medical Oncology Clinic


    AREAS OF INTEREST

    Lung cancer

    esophageal cancer

    Gastric cancer

    breast cancer

    Gastrointestinal surgery

    https://scholar.google.com.tr/citations?user=EDuylhoAAAAJ&hl=tr 

  • Baca selengkapnya
Kemoterapi
$4,000 - $5,000
Info

Ahmet Bilici

  • Dokter terkemuka untuk Kemoterapi
  • 4.6 Sangat baik 472 ulasan
  • 28 tahun pengalaman
  • Turquia, Istambul, Medipol Mega University Hospital
  • Dr. Ahmet Bilici adalah seorang onkolog medis ternama yang berspesialisasi dalam sarkoma dan kanker paru-paru dengan pengalaman lebih dari 20 tahun.

    • Salah satu dokter sarkoma dan kanker paru-paru terbaik di Turki
    • Keahlian luas dalam pengobatan onkologi
    • Berpraktik di Rumah Sakit Universitas Medipol Mega
  • Baca selengkapnya
Info

Mehmet Faik Cetindag

  • 4.6 Sangat baik 472 ulasan
  • 35 tahun pengalaman
  • Turquia, Istambul, Medipol Mega University Hospital
  • Dengan lebih dari 30 tahun spesialisasi di bidang onkologi, Dr. Cetindag telah memberikan kontribusi signifikan terhadap penelitian kanker kepala dan leher di Rumah Sakit Universitas Medipol Mega.

    • Ahli dalam kemoterapi, radioterapi, dan prostatektomi
    • Menerbitkan 22 artikel jurnal internasional tentang onkologi
    • Mempresentasikan penelitian pada 14 pertemuan ilmiah internasional
    • Gelar kedokteran dari Universitas Hacettepe
  • Baca selengkapnya
Info

Mustafa Serkan Alemdar

  • 4.5 Baik 6 ulasan
  • 20 tahun pengalaman
  • Turquia, Antália, Medical Park Antalya Hospital Complex
  • Education and Specialization

    • 2006: Kocaeli University Faculty of Medicine
    • 2014: Akdeniz University Faculty of Medicine, Internal Medicine
    • 2018: Akdeniz University Faculty of Medicine, Medical Oncology

    Experience

    • 2006 - 2008: Konya Derebucak District Hospital
    • 2009 - 2015: Akdeniz University Hospital
    • 2015: Antalya Kaş State Hospital
    • 2015 - 2016: İnönü University Faculty of Medicine
    • 2016 - 2021: Akdeniz University Hospital
    • 2021 - 2023: Antalya Training and Research Hospital
  • Baca selengkapnya
Kunjungan dokter
Harga berdasarkan permintaan
Info

Ozcan Yildiz

  • 4.6 Sangat baik 472 ulasan
  • 76 tahun pengalaman
  • Turquia, Istambul, Medipol Mega University Hospital
  • Dr. Yildiz telah memublikasikan lebih dari 17 makalah penelitian tentang berbagai topik onkologi, dengan fokus pada tumor neuroendokrin dan sindrom paraneoplastik.

    • Berspesialisasi dalam tumor neuroendokrin gastroenteropankreatik
    • Dipublikasikan di Medical Oncology dan jurnal tinjauan sejawat lainnya
    • Berpengalaman dalam menangani kasus kemoterapi yang kompleks
    • Bekerja di Rumah Sakit Universitas Medipol Mega
  • Baca selengkapnya
Info

Sema Anak

  • 4.6 Sangat baik 472 ulasan
  • 45 tahun pengalaman
  • Turquia, Istambul, Medipol Mega University Hospital
  • Berspesialisasi dalam onkologi pediatri – Dr. Anak berfokus secara eksklusif pada pengobatan anak-anak penderita kanker di Rumah Sakit Universitas Medipol Mega.

    • Ahli dalam hematologi dan onkologi pediatri
    • Berdedikasi untuk menyediakan perawatan yang disesuaikan untuk pasien muda
    • Bekerja di rumah sakit universitas terkemuka dengan fasilitas canggih
  • Baca selengkapnya
Info

Tahsin Ozatli

  • Dokter terkemuka untuk Kemoterapi
  • 4.4 Baik 17 ulasan
  • 2016 tahun pengalaman
  • Turquia, Istambul, Istinye University Liv Hospital Bahcesehir
  • Berspesialisasi dalam kanker payudara, paru-paru, dan gastrointestinal – Profesor Madya Tahsin Ozatli merawat pasien di Rumah Sakit Universitas Istinye Liv.

    • Spesialis Penyakit Dalam dengan pengalaman di berbagai rumah sakit di Turki
    • Mantan dokter di Departemen Onkologi di Rumah Sakit Pelatihan dan Penelitian Regional Erzurum
    • Profesor Madya sejak 2016
    • Lulusan dari Fakultas Kedokteran Universitas Selcuk
  • Baca selengkapnya
Kemoterapi
$2,000 - $9,000
Info

Cemil Bilir

  • 5 Sangat baik 1 ulasan
  • 21 tahun pengalaman
  • Turquia, Istambul, VM Medical Park Pendik Hospital
  • Education & Expertise

    • 1998 to 2004 – Istanbul University, Istanbul Faculty of Medicine
    • 2005 to 2009 – Düzce University, Internal Medicine Specialization
    • 2009 to 2010 – Beytüşşebap State Hospital, Compulsory Internal Medicine Service
    • 2010 to 2013 – Bülent Ecevit University, Medical Oncology Specialization
    • 2013 to 2015 – Recep Tayyip Erdoğan University, Medical Oncology Compulsory Service
    • 2015 to Present – Associate Professor, Recep Tayyip Erdoğan University
    • 2015 to 2021 – Lecturer, Medical Oncology, Sakarya University Faculty of Medicine
    • 2020 to Present – Professor, Sakarya University Faculty of Medicine
    • 2020 to Present – Ph.D. Student, Inorganic Chemistry, Sakarya University

    Experience

    • 2008 – Cleveland Clinic, Rheumatology & Gastroenterology Rotation
    • 2016 to 2017 – Northeastern University, The Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, U.S.

    Professional Memberships

    • TTOD (Turkish Society of Medical Oncology)
    • ASCO (American Society of Clinical Oncology)
    • ESMO (European Society for Medical Oncology)
  • Baca selengkapnya
Kunjungan dokter
Harga berdasarkan permintaan
Info

Yusuf Acikgoz

  • 4.9 Sangat baik 7 ulasan
  • 10 tahun pengalaman
  • Turquia, Ancara, Lokman Hekim University Ankara Hospital
  • Associate Professor Dr. Yusuf AÇIKGÖZ
    Specialization: Medical Oncology

    Education:

    • 2004-2011: İnönü University Faculty of Medicine
    • 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
    • 2017-2022: Health Sciences University, Medical Oncology

    Professional Experience:

    • 2016-2017: Bingöl City Hospital, Internal Medicine
    • 2021-2022: Health Sciences University, Medical Oncology
    • 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
    • 2023-2024: Ohio State University, Medical Oncology
    • 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

    Clinical Trials, Courses, Certifications:

    Clinical Trials:

    • 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
    • 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

    Courses:

    • 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
    • 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
    • 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
    • 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
    • 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

    Certifications:

    • Ongoing: ECFMG Certification
    • 2024: CITI Responsible Conduct of Research (The Ohio State University)
    • 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
    • 2024: CITI Human Subjects Protection (The Ohio State University)
    • 2024: CITI Good Clinical Practice (The Ohio State University)
    • 2023: Occupational English Test (OET)
    • 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
    • 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
    • 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

    Memberships:

    • American Society of Clinical Oncology (ASCO) - 2022
    • Turkish Society of Medical Oncology - 2020
  • Baca selengkapnya
Kunjungan dokter
Harga berdasarkan permintaan
Info

Hasan Atilla Ozkan

  • 5 Sangat baik 1 ulasan
  • 23 tahun pengalaman
  • Turquia, Istambul, VM Medical Park Pendik Hospital
  • Education & Expertise

    • 1997 | Hacettepe University Faculty of Medicine – Medical Degree
    • 2003 | Uludağ University Faculty of Medicine – Internal Medicine Specialization
    • 2007 | Uludağ University Faculty of Medicine – Hematology Subspecialty

    Professional Experience

    • 1998 (May – September) | Practitioner, Dr. Salaha Health Center, Rize
    • 1998 to 2003 | Research Assistant, Uludağ University Faculty of Medicine, Internal Medicine Department
    • 2003 to 2007 | Hematology Subspecialist, Uludağ University Faculty of Medicine, Hematology Division
    • 2007 to 2011 | Hematology Specialist, Bursa Ali Osman Sönmez Oncology Hospital (Compulsory Service)
    • 2011 to 2013 | Hematology Specialist, Private Anadolu Health Center Bone Marrow Transplant Center, Gebze
    • 2014 to 2015 | Assistant Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine
    • 2015 to 2020 | Associate Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine
    • 2020 to Present | Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine

    Courses & Certifications

    • Autologous and Allogeneic Stem Cell Transplantation Certificate
    • Clinical Phytotherapy Application Certificate
    • Flow Cytometry Experience Certificate
    • EBMT Stem Cell Transplantation Course

    Professional Memberships

    • Turkish Medical Chamber
    • Turkish Hematology Association (Full Member, No: 893)
    • Turkish Therapeutic Apheresis Association (Current President)
    • Geriatric Hematology Association
    • Hematological Oncology Association
    • EBMT (European Bone Marrow Transplantation)

    Awards & Recognitions

    • 2011 | 6th Turkish Therapeutic Apheresis Congress – Young Researcher Award
  • Baca selengkapnya
Kunjungan dokter
Harga berdasarkan permintaan
Info

Tarik Salman

  • Baru
  • 32 tahun pengalaman
  • Turquia, Esmirna, Medicalpoint International Hospital
  • Diseases

    • Lung Cancer
    • Skin Cancers
    • Gastrointestinal Cancers
    • Genitourinary Cancers
    • Gynecological Cancers
    • Colon Cancer
    • Breast Cancer
    • Rare Cancers

    Treatment Methods

    • Individual Treatments (Comprehensive Genomic Profiling)
    • Targeted Therapies
    • Immunotherapy
    • Cancer Vaccines
    • Chemotherapy
    • Clinical Research/Experimental Medical Research

    Experience

    • 2017- 2024: Katip Çelebi University Faculty of Medicine Atatürk Education and Research Hospital Medical Oncology Clinic Associate Professor / Lecturer
    • 2022 December – 2023 March: Academic visitor Moffitt Cancer Center Cutaenous Oncology Clinic Tampa, Florida USA
    • 2013- 2017: Katip Çelebi University Faculty of Medicine Atatürk Training and Research Hospital – Medical Oncology Clinic Specialist Physician
    • 2012-2013: Izmir Education and Research Hospital, Medical Oncology Specialist Physician
    • 2012-2012: Mersin State Hospital, Medical Oncology Specialist Physician
    • 2010-2012: Dokuz Eylül University Faculty of Medicine, Department of Medical Oncology, Sub-branch Research Assistant
    • June-August 2008, December 2008 – February 2009: Memorial Sloan Kettering Cancer Center Observership programme
    • 2007-2009: Kartal Education and Research Hospital, Medical Oncology Sub-branch Research Assistant
    • 2006-2007: Siirt State Hospital, Internal Medicine, Specialist Physician
    • 2005-2006: Çukurova University Faculty of Medicine, Medical Oncology Sub-branch Research Assistant
    • 2004-2005: SSK Siirt Hospital, Internal Medicine Specialist Physician
    • 2003-2004: SSK Mardin Hospital, Internal Medicine Specialist Physician
    • 1998-2003: SSK Izmir Training and Research Hospital, 3rd Internal Medicine Clinic, Research Assistant
    • 1998-1998: SSK Izmir Training and Research Hospital Infectious Diseases Research Assistant
    • 1997-1998: Izmir Ataturk Training and Research Hospital, Anesthesiology and Reanimation Clinic, Research Assistant
    • 1995-1997: Şırnak Cizre Central Health Center
    • 1994-1995: Şırnak İdil Oyalı Village Health Center

    Professional Memberships

    • Turkish Society of Medical Oncology 2008 
    • (2018-2021 Term Board Member)
    • Izmir Oncology Group, Board Member (2014 -…)
    • Geriatric Oncology Association, Board Member (2015-…)
    • Mediterranean Oncology Association Board Member (2020 -…)
    • Turkish Biochemistry Association, Member, 2016
    • European Society of Medical Oncology, Member, 2012
    • American Society of Clinical Oncology, Member, 2008
  • Baca selengkapnya
Kunjungan dokter
Harga berdasarkan permintaan
Info

Nail Paksoy

  • 4.5 Baik 2 ulasan
  • 15 tahun pengalaman
  • akreditasi:
  • Turquia, Istambul, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Baca selengkapnya
Kunjungan dokter
Harga berdasarkan permintaan
Info

Ercan Ozden

  • 5 Sangat baik 1 ulasan
  • 27 tahun pengalaman
  • Turquia, Istambul, VM Medical Park Pendik Hospital
  • Dr. Ercan Ozden berspesialisasi dalam kemoterapi, menggabungkan pengalaman bertahun-tahun dalam keahlian penyakit dalam dengan pelatihan onkologi medis yang terfokus di Universitas Kocaeli.

    • Bersertifikasi dewan dalam penyakit dalam dengan lebih dari 16 tahun pengalaman klinis
    • Menjalani pelatihan di Fakultas Kedokteran Cerrahpaşa yang bergengsi di Universitas Istanbul
    • Menyelesaikan subspesialisasi onkologi medis di Universitas Kocaeli
    • Telah bekerja di berbagai lingkungan rumah sakit, dari rumah sakit negara hingga rumah sakit universitas
  • Baca selengkapnya
Kunjungan dokter
Harga berdasarkan permintaan
Info

Bookimed Insights: Top Kemoterapi Specialists in Turquia ()

Bookimed has coordinated 63 requests for Kemoterapi in Turquia, collaborating with 57 top-rated specialists. The doctors in this table are selected based on their international credentials, clinical expertise, and patient outcomes. The ranking is formed using verified data from actual patient cases and current programs from our partner clinics.
DokterpengalamanGood Fit ForWhat Sets Them ApartClinic & LocationConsultation
26 tahun pengalamanKasus limfoma pediatrikSpesialis limfoma pediatrik terkemuka dengan pelatihan dari MD Anderson. Memimpin departemen di Anadolu Medical Center. Telah menerbitkan lebih dari 70 makalah penelitian dan 5 buku teks.
Turquia
Harga berdasarkan permintaan
46 tahun pengalamanPerawatan kemoterapiProfesor Onkologi dan Hematologi dengan latar belakang akademis yang kuat, memastikan protokol pengobatan yang canggih. Berpraktik di Anadolu Medical Center.
Turquia
Harga berdasarkan permintaan
28 tahun pengalamanSarkoma dan kanker paru-paruTernama karena keahliannya dalam sarkoma dan kanker paru-paru – salah satu spesialis teratas Turki di bidang ini. Berpraktik di Rumah Sakit Universitas Medipol Mega.
Turquia
dari $115
35 tahun pengalamanKanker kepala dan leherPeneliti terkemuka dalam kanker kepala dan leher dengan 22 publikasi internasional. Lebih dari tiga dekade praktik onkologi khusus di rumah sakit terkemuka di Turki.
Turquia
Harga berdasarkan permintaan
76 tahun pengalamanTumor neuroendokrinTelah banyak menerbitkan publikasi mengenai tumor neuroendokrin dan sindrom paraneoplastik. Memiliki keahlian dalam penanganan kasus kemoterapi kompleks, dengan penelitian yang diterbitkan di jurnal Onkologi Medis.
Turquia
Harga berdasarkan permintaan
45 tahun pengalamanOnkologi pediatrikBerfokus secara eksklusif pada onkologi pediatrik – berspesialisasi dalam merawat anak-anak dengan kanker. Bekerja di Rumah Sakit Universitas Medipol Mega dengan fasilitas canggih.
Turquia
Harga berdasarkan permintaan
2016 tahun pengalamanKanker payudara, paru-paru, dan gastrointestinalBerspesialisasi dalam kanker payudara, paru-paru, dan gastrointestinal, dengan pengalaman di berbagai rumah sakit. Profesor Madya sejak 2016.
Turquia
Harga berdasarkan permintaan
27 tahun pengalamanRencana pengobatan kemoterapiMenggabungkan perspektif ilmu penyakit dalam umum dengan pelatihan onkologi spesialis. Telah bekerja di berbagai tingkatan rumah sakit, termasuk pusat akademik.
Turquia
Harga berdasarkan permintaan